share_log

Vanda Pharmaceuticals Q2 EPS $0.05 Misses $0.11 Estimate, Sales $64.40M Miss $67.00M Estimate

Vanda Pharmaceuticals Q2 EPS $0.05 Misses $0.11 Estimate, Sales $64.40M Miss $67.00M Estimate

万达制药第二季度每股收益0.05美元未达到0.11美元预期,销售额6440万美元未达到6700万美元预期
Benzinga Real-time News ·  2022/08/03 16:30

Vanda Pharmaceuticals (NASDAQ:VNDA) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.11 by 54.55 percent. This is a 70.59 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $64.40 million which missed the analyst consensus estimate of $67.00 million by 3.88 percent. This is a 5.15 percent decrease over sales of $67.90 million the same period last year.

万达制药(纳斯达克:VNDA)公布季度收益为每股0.05美元,低于分析师一致预期的0.11美元,增幅为54.55%。这比去年同期每股0.17美元的收益下降了70.59%。该公司公布季度销售额为6,440万美元,低于分析师一致预期的6,700万美元,降幅为3.88%。这比去年同期6790万美元的销售额下降了5.15%。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发